BBRRF - Blueberries Medical Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1080
-0.0150 (-12.20%)
At close: 3:23PM EDT
Stock chart is not supported by your current browser
Previous Close0.1230
Open0.1210
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1080 - 0.1220
52 Week Range0.0300 - 0.6500
Volume47,512
Avg. Volume58,180
Market Cap11.459M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    Blueberries Medical Receives Approval for Commercial Production & Registration of Five Proprietary CBD Cultivars from the Colombian Institute of Agriculture

    Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that the Company has received approval from the Colombian Institute of Agriculture (“ICA”) for the registration of five proprietary non-psychoactive cannabidiol (CBD) strains with the national cultivar registry and to commence commercial production of these strains. The registration and approval to commence commercial production is amongst the first to be issued in Colombia and a major milestone for the Company.

  • GlobeNewswire

    Blueberries Medical and The Colombian Society of Pediatrics Partner to Host Medicinal Cannabis Seminar in Bogota

    Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that the Company has partnered with The Colombian Society of Pediatrics to host a full-day educational seminar for medical practitioners and other industry participants on the therapeutic benefits of medicinal cannabis and current industry developments. This event is part of the Company’s ongoing initiatives focused on the development of medical education programs for physicians and patients in Latin America.

  • GlobeNewswire

    Blueberries Medical Announces Internationally Renowned Medical & Scientific Committee

    Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or "Blueberries"), a leading Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce the formation of its medical & scientific committee to support management in the development of leading-edge formulations as well as its ongoing commercial and educational initiatives. Leveraging their unique and collective expertise in the healthcare industry in South and North America, the Blueberries medical & scientific committee is focused on the development of innovative formulations to treat specific pathologies, as well as safe and effective treatment regimes.

  • GlobeNewswire

    Blueberries Medical Corp. Closes Over-Subscribed Private Placement

    Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or "Blueberries"), a leading Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce it has closed its over-subscribed, non-brokered private placement (the “Offering”) of units (the “Units”) at a price of C$0.25 per Unit for total gross proceeds of C$3,457,500. Each Unit consists of one common share in the capital of the Company (a “Share”) and one Share purchase warrant (a “Warrant”). This is an exciting time of growth for the company and this capital will allow us to invest in and scale our business effectively,” stated Dr. Patricio Stocker, Chief Executive Officer.

  • GlobeNewswire

    Blueberries Medical Announces $3 Million Non-Brokered Private Placement

    Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or "Blueberries"), a leading Latin American licensed producer of medicinal cannabis and cannabis-derived products, announces a non-brokered private placement of up to 12,000,000 units (the “Units”) at a price of C$0.25 per Unit for gross proceeds of up to C$3,000,000 (the “Offering”). Each Unit will consist of one common share in the capital of the Company (a “Share”) and one Share purchase warrant (a “Warrant”).

  • GlobeNewswire

    Blueberries Medical Makes Significant Advances Towards Commercial Production & Provides Operational and Corporate Update

    Expansion of Cultivation Facilities: Newly constructed open-air greenhouses completed and fully operational, increasing initial production capacity by approximately 40% to 150,000 sq.ft. Upgrade to facility infrastructure, including irrigation and electrical systems, water reservoirs and propagation facility also completed. Extraction: Customized extraction line with capacity to process up to 75,000 kg/year of dried flower currently undergoing specializations and customization to meet EU-GMP standards. Strategic Partnerships: Announced several strategic partnerships including (i) an agreement with SLANG Worldwide (CSE:SLNG) (“Slang”) announced on July 11, 2019 to license their extensive portfolio of CPG (Consumer Packaged Goods) products and leverage Slang’s industry leading know-how and intellectual property to process and formulate cannabis products in Colombia and Argentina, (ii) a distribution agreement announced on February 14, 2019 with El Manantial, a local medical center network and (iii) a European distribution agreement announced on June 5, 2019.

  • GlobeNewswire

    Blueberries Announces DTC Eligibility of its Common Shares in the United States

    Blueberries Medical Corp. (CSE: BBM) (BBRRF) (1OA.F) ("Blueberries" or the "Company"), a leading Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that the Company’s common shares, traded in the United States under the symbol BBRRF, are now eligible for electronic clearing and settlement through the Depository Trust Company in the United States. Dr. Patricio Stocker, CEO of Blueberries commented: "DTC eligibility will allow current and prospective Blueberries shareholders more reliable, cost-efficient, and timely clearing and settlement for our common shares.

  • GlobeNewswire

    Blueberries Executes Definitive Agreement to Acquire Cannabis Cultivation, Processing & Manufacturing Rights for 3.2M Square Foot Property in Argentina

    Further to its news releases dated March 26 and April 4, 2019, Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or "Blueberries"), a leading Colombia based licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that the Company has entered into a definitive share purchase agreement to acquire cannabis cultivation, processing, manufacturing and other rights in Argentina (the “Share Purchase Agreement”) from BBV Labs Inc. (“BBV Labs”). Pursuant to a definitive joint venture agreement with the Argentinean state-owned company Cannabis Avatara, S.E. (“Cannava”), BBV Labs entered into a joint venture (the “Joint Venture”) with Cannava to develop and cultivate cannabis on a 3.2 million square foot (74 acres or 30 hectares) prime agricultural property.

  • GlobeNewswire

    Blueberries Announces Appointment of Chief Financial Officer

    Blueberries Medical Corp. (CSE: BBM) (BBRRF) (1OA.F) ("Blueberries" or the "Company"), a leading Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce the appointment of Ian D. Atacan CPA, CMA, MBA, B.Sc. Mr. Reid will work with Mr. Atacan and the Company to support a seamless transition, and the Company would like to thank Mr. Reid for his services.

  • GlobeNewswire

    Blueberries and SLANG Worldwide Enter into Strategic Partnership for Colombia and Argentina

    TORONTO, June 11, 2019 -- Blueberries Medical Corp. (CSE: BBM) (OTCQB: BBRRF) (FRA: 1OA) ("Blueberries"), a leading Latin American licensed producer of medicinal cannabis and.

  • GlobeNewswire

    Blueberries Announces Cannabis Sales and Distribution Agreement for German Market

    Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or "Blueberries"), a leading Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that it has entered into a letter agreement (the "Letter Agreement") to become a strategic supplier of medical cannabis products to Canurius UG (“Canurius”), for the sale and distribution of cannabis products in Germany with the potential for expansion into Austria, Switzerland and the Netherlands. Pursuant to the terms of the Letter Agreement, Blueberries will provide Canurius with approximately 100 litres (100 kg) of cannabis oil extract per month for an initial 12-month term.

  • GlobeNewswire

    Blueberries Receives Approval to Sell Five CBD Wellness Products in Colombia and Internationally from Colombian Food and Drug Regulator

    Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or "Blueberries"), a leading Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that the Company has received approval for the production, sale and export of five cannabidiol ("CBD") based health and wellness products from the Instituto Nacional de Vigilancia de Medicamentos y Alimentos ("INVIMA"), the Colombian National Food and Drug Surveillance Institute.

  • CNW Group

    Latin American Countries Offer Unique Benefits to Cannabis Cultivators

    Predominantly, most countries which have adopted cannabis legislation have legalized the plant specifically for medical purposes. Countries such as Argentina, Chile, Colombia, and Brazil have all legalized medical cannabis, while some have also decriminalized cannabis, allowing for moderate personal consumption. In combination, all of these factors are further accelerating the Latin American cannabis industry by inviting new business opportunities.

  • GlobeNewswire

    Blueberries Medical Appoints Former Abbott Laboratories/AbbVie Pharmaceutical Executive Eduardo Molinari as Chief Marketing Officer

    Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or "Blueberries") a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce the appointment of Eduardo Molinari, a former executive of Abbott Laboratories (ABT) (“Abbott”) and AbbVie Ltd. (ABBV) (“AbbVie”) as Chief Marketing Officer. Mr. Molinari will lead the development and implementation of the Company’s marketing strategies, directing these initiatives in the local and international markets.

  • CNW Group

    Tourists Find New and Destination-Worthy Attractions in Cannabis

    Additionally, a survey conducted by Colorado Tourism reported that 12 million, or approximately 15%, of those travelers participated in marijuana-related activities. Around the world, even though the cannabis industry remains in its infancy stage, more and more countries continue to legalize the plant. Thusly, the consumer base is projected to grow, propelling the overall market even further, as according to data compiled by Mordor Intelligence, the global cannabis market was valued at USD 7.7 Billion in 2016 and is expected to reach USD 65 Billion by 2023.

  • GlobeNewswire

    Blueberries Medical to Collaborate with the International Research Center on Cannabis and Mental Health in New York for Product Formulation and the Development of Treatment-Focused Medical Education Programs

    Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or "Blueberries") a Latin American licenced producer of medicinal cannabis and cannabis-derived products, has signed a definitive joint venture agreement (the “Agreement”) with the International Research Center on Cannabis and Mental Health (“IRCCMH” or the “Center”) for the development of medical education programs for physicians and patients in Latin America and product formulation. IRCCMH is a leading research and academic organization in the cannabis sector with extensive experience in cannabis research and education, pharmacology, product formulation and the efficacy of cannabis-based treatments. Based in New York and aligned with the Silver School of Social Work at New York University, IRCCMH is comprised of renowned scientists, educators and clinicians and was created to bridge a gap between research and clinical practice.

  • GlobeNewswire

    Blueberries Medical to Present at 2019 GMP Securities’ Global Cannabis Conference

    Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or "Blueberries") a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that the Company’s executive management team will attend and present at GMP Securities’ 2019 Global Cannabis Conference on April 16, 2019 at The Ritz-Carlton, Toronto. The GMP Securities’ Global Cannabis Conference will explore current investing trends, industry perspectives on consumer trends and key developments.

  • GlobeNewswire

    Blueberries Medical Commences Formal Development Process for the Cultivation of Cannabis in Jujuy Argentina

    Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or "Blueberries"), a Latin American focused licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that it has commenced the Phase 1 planning process with Argentinian state owned cannabis company Cannabis Avatara, S.E. (“Cannava”) in connection with the cooperation agreement entered into under the scope of the “Provincial Program of Promotion of the Cultivation and Production of Cannabis with Scientific, Medicinal and Therapeutic Purposes of the Province of Jujuy in Argentina” (the “Joint Venture”), through its agreement with BBV Labs Inc. as recently announced by the Company.

  • GlobeNewswire

    Blueberries Medical Commences Trading in the United States on OTCQB Market Under Symbol BBRRF

    Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or "Blueberries"), a leading Colombia based licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that its common shares will commences trading on the OTCQB Market (the “OTCQB”) today under the ticker symbol “BBRRF”. OTCQB is a trading platform in the United States operated by the OTC Markets Group in New York which provides real-time quotations and market data to a broad network of broker-dealers and retail investors.

  • CNW Group

    FinancialBuzz.com Exclusive Interview With Chief Operating Officer, Camilo Villalba of Blueberries Medical Corp. Live on Wall Street in New York City

    NEW YORK , March 22, 2019 /CNW/ --  FinancialBuzz.com , a respected source in the financial news media space located on Wall Street, today announces an exclusive video interview with Chief Operating Officer, Camilo ...

  • GlobeNewswire

    Blueberries Medical Appoints Former Colombian Minister & Ambassador Fabio Valencia to Board of Directors

    Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or "Blueberries"), a leading Colombia-based licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce the appointment of Fabio Valencia Cossio, a former Colombian Minister, Senator and Ambassador to Italy with extensive strategic international business experience to its board of directors. “We are honored to welcome Mr. Valencia to our board of directors and are confident that his vast experience in public policy and international business will be a valuable addition to our leadership team,” stated Christian Toro, Chief Executive Officer.

  • Baystreet

    The Top Cannabis Stocks with a Powerful Colombian Market Catalyst

    With favorable cannabis-growing conditions, Colombia is quickly emerging as an industry hot spot. In ...

  • Baystreet

    CBD: The Top Cannabis Beverage Stocks to Own in 2019

    The CBD boom is just in the early stages of major growth. Thanks to growing acceptance, including ...

  • CNW Group

    Cannabis Businesses Eye Latin America in Effort to Reduce Costs

    NEW YORK, Feb. 14, 2019 The cannabis industry is an attractive investment opportunity for entrepreneurs, however, entering into the market poses a challenge for many. In order to mitigate their losses, many began to establish operations in Latin America, specifically in countries such as Argentina, Brazil, Chile, Colombia, and Peru. According to data compiled by BDS Analytics in partnership with Arcview Research, the South American legal cannabis spending is expected to grow from USD 125 Million in 2018 to USD 776 Million by 2026.